Merus Shares Soar Premarket After Takeover Deal With Genmab

Dow Jones

Sep 29

By Colin Kellaher

Shares of Merus surged in premarket trading Monday after the clinical-stage biotechnology company agreed to be acquired by Danish biotech Genmab for about $8 billion.

Genmab said it will pay $97 a share in cash for Merus, a roughly 41% premium to Friday's closing price of $68.89 for the Utrecht, Netherlands, company.

The deal is slated to close by early in the first quarter of 2026.

Merus shares were recently up 38% to $95.20 in premarket trading.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

September 29, 2025 05:55 ET (09:55 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2571389132"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571389132\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571389132?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 17:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571389132","market":"hk","top_or_hot":-1,"title":"Merus Shares Soar Premarket After Takeover Deal With Genmab","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Merus surged in premarket trading Monday after the clinical-stage biotechnology company agreed to be acquired by Danish biotech Genmab for about $8 billion. \n</p>\n<p>\n  Genmab said it will pay $97 a share in cash for Merus, a roughly 41% premium to Friday's closing price of $68.89 for the Utrecht, Netherlands, company. \n</p>\n<p>\n  The deal is slated to close by early in the first quarter of 2026. \n</p>\n<p>\n  Merus shares were recently up 38% to $95.20 in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 29, 2025 05:55 ET (09:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merus Shares Soar Premarket After Takeover Deal With Genmab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerus Shares Soar Premarket After Takeover Deal With Genmab\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-09-29 17:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Merus surged in premarket trading Monday after the clinical-stage biotechnology company agreed to be acquired by Danish biotech Genmab for about $8 billion. \n</p>\n<p>\n  Genmab said it will pay $97 a share in cash for Merus, a roughly 41% premium to Friday's closing price of $68.89 for the Utrecht, Netherlands, company. \n</p>\n<p>\n  The deal is slated to close by early in the first quarter of 2026. \n</p>\n<p>\n  Merus shares were recently up 38% to $95.20 in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 29, 2025 05:55 ET (09:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GMAB","symbol_name":"Genmab A/S","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2571389132","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571389132","pubTimestamp":1759139700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Merus surged in premarket trading Monday after the clinical-stage biotechnology company agreed to be acquired by Danish biotech Genmab for about $8 billion.Genmab said it will pay $97 a share in cash for Merus, a roughly 41% premium to Friday's closing price of $68.89 for the Utrecht, Netherlands, company.The deal is slated to close by early in the first quarter of 2026.Merus shares were recently up 38% to $95.20 in premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GMAB":"Genmab A/S","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","MRUS":"Merus B.V.","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD"},"translate_title":"与Genmab达成收购协议后，Merus股价盘前飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GMAB":0.9,"MRUS":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Shares of Merus surged in premarket trading Monday after the clinical-stage biotechnology company agreed to be acquired by Danish biotech Genmab for about $8 billion. \n\n\n  Genmab said it will pay $97 a share in cash for Merus, a roughly 41% premium to Friday's closing price of $68.89 for the Utrecht, Netherlands, company. \n\n\n  The deal is slated to close by early in the first quarter of 2026. \n\n\n  Merus shares were recently up 38% to $95.20 in premarket trading. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 29, 2025 05:55 ET (09:55 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}